- Home
- HFFG vs KLRS Comparison
HFFG vs KLRS Comparison
Compare HFFG & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HFFG | KLRS |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United States | United States |
| Employees | 960 | 20 |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.8M | 113.0M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | HFFG | KLRS |
|---|---|---|
| Price | $1.67 | $4.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 408.7K | 63.9K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.65 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,228,282,000.00 | N/A |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | $83.75 | ★ N/A |
| Revenue Growth | ★ 2.21 | N/A |
| 52 Week Low | $1.38 | $2.14 |
| 52 Week High | $3.86 | $11.88 |
Technical Indicators
Market Signals| Indicator | HFFG | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 47.53 |
| Support Level | $1.40 | $4.20 |
| Resistance Level | $2.27 | $4.86 |
| Average True Range (ATR) | 0.14 | 0.45 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 44.44 | 25.11 |
Price Performance
Historical ComparisonAbout HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, frozen and dry food, and non-food products to Asian restaurants and other foodservice customers throughout the United States. The company's business consists of one operating segment: HF Group, which operates solely in the United States. The company's product list consists of Meat, Poultry & Seafood, Sauces & Oils, Takeout Items (Boxes, Chopsticks & Utensils), Raw Ingredients (Flour, Cornstarch, Spices), Cleaning Supplies, and Rice & Grains.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.